GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savient Pharmaceuticals (FRA:BY7) » Definitions » E10

Savient Pharmaceuticals (FRA:BY7) E10 : €0.00 (As of Sep. 2013)


View and export this data going back to . Start your Free Trial

What is Savient Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Savient Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2013 was €0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Sep. 2013.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-15), Savient Pharmaceuticals's current stock price is €0.03. Savient Pharmaceuticals's E10 for the quarter that ended in Sep. 2013 was €0.00. Savient Pharmaceuticals's Shiller PE Ratio of today is .


Savient Pharmaceuticals E10 Historical Data

The historical data trend for Savient Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savient Pharmaceuticals E10 Chart

Savient Pharmaceuticals Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.20 -0.44 -0.47 -0.67 -1.04

Savient Pharmaceuticals Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Mar14
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.04 -1.09 -1.11 - -

Competitive Comparison of Savient Pharmaceuticals's E10

For the Biotechnology subindustry, Savient Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savient Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savient Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Savient Pharmaceuticals's Shiller PE Ratio falls into.



Savient Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Savient Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2013 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2013 (Change)*Current CPI (Sep. 2013)
=0/98.7900*98.7900
=0.000

Current CPI (Sep. 2013) = 98.7900.

Savient Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
200312 0.049 77.758 0.062
200403 0.016 79.066 0.020
200406 -0.436 80.037 -0.538
200409 -0.057 80.121 -0.070
200412 0.000 80.290 0.000
200503 -0.045 81.555 -0.055
200506 -0.008 82.062 -0.010
200509 -0.025 83.876 -0.029
200512 0.126 83.032 0.150
200603 0.050 84.298 0.059
200606 0.040 85.606 0.046
200609 0.794 85.606 0.916
200612 -0.076 85.142 -0.088
200703 -0.113 86.640 -0.129
200706 -0.134 87.906 -0.151
200709 -0.201 87.964 -0.226
200712 -0.220 88.616 -0.245
200803 -0.213 90.090 -0.234
200806 -0.289 92.320 -0.309
200809 -0.237 92.307 -0.254
200812 -0.333 88.697 -0.371
200903 -0.314 89.744 -0.346
200906 -0.657 91.003 -0.713
200909 -0.158 91.120 -0.171
200912 0.034 91.111 0.037
201003 -0.096 91.821 -0.103
201006 -0.057 91.962 -0.061
201009 -0.679 92.162 -0.728
201012 -0.005 92.474 -0.005
201103 -0.135 94.283 -0.141
201106 -0.298 95.235 -0.309
201109 -0.284 95.727 -0.293
201112 -0.334 95.213 -0.347
201203 -0.371 96.783 -0.379
201206 -0.183 96.819 -0.187
201209 -0.435 97.633 -0.440
201212 -0.300 96.871 -0.306
201303 -0.262 98.209 -0.264
201306 -0.265 98.518 -0.266
201309 0.000 98.790 0.000

Add all the adjusted EPS together and divide 10 will get our e10.


Savient Pharmaceuticals  (FRA:BY7) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Savient Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Savient Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Savient Pharmaceuticals (FRA:BY7) Business Description

Traded in Other Exchanges
N/A
Address
Savient Pharmaceuticals, Inc., was founded in 1980. It develops, manufactures and markets products through the application of genetic engineering and related biotechnologies. The Company, and its wholly-owned Subsidiaries, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. It completed a promotional launch of KRYSTEXXA in the United States during the first quarter of 2011 with its sales force commencing field promotion to health care providers on February 28, 2011. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company launched its authorized generic version of oxandrolone in December 2006 in response to the approval and launch of generic competition to Oxandrin. On January 1, 2012, KRYSTEXXA received a permanent J Code, which facilitates reimbursement to providers who treat patients suffering with RCG and who rely on Medicare and Medicaid. The manufacturing process for pegloticase, which is the drug substance of KRYSTEXXA, consists of the production through a recombinant process in which a genetically-engineered bacteria produces uricase, followed by its purification, PEGylation, further purification and formulation to produce the bulk pegloticase, which the company refers it as pegloticase drug substance. Pegloticase is aseptically filtered and filled into sterile, single dose vials to produce the KRYSTEXXA drug product. Its sales force targets rheumatologists and nephrologists with access to infusion centers and healthcare institutions, each of which treat adult patients suffering from RCG, as well as podiatrists who also treat patients with RCG. In March 2012, KRYSTEXXA was made available in the EU to healthcare professionals through a Named Patient Program. The Company sells its products to three drug wholesaler customers and various specialty distributors. Its research and development includes costs associated with the research and development of its KRYSTEXXA product prior to FDA approval and FDA-related post-marketing commitments for approved products (KRYSTEXXA post-approval). These costs mainly include pre-clinical and clinical studies and trials, personnel costs including compensation, consultants and contract research organizations, or CROs, quality control and assurance costs, regulatory costs and costs related to the development of commercial scale manufacturing capabilities for KRYSTEXXA, which also includes the costs of preparing Fujifilm to serve as its secondary source supplier of pegloticase drug substance for KRYSTEXXA in the United States. As of March 7, 2013, the company owned 14 issued U.S. patents and 154 issued foreign patents. It currently owns U.S. and several foreign registrations or applicat

Savient Pharmaceuticals (FRA:BY7) Headlines

No Headlines